EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of the Effectiveness of Buprenorphine-Naloxone on Opioid Overdose and Death among Insured Patients with Opioid Use Disorder in the United States

Tianyu Sun iD, Natallia Katenka, Stephen Kogut, Jeffrey Bratberg iD, Josiah Rich, Ashley Buchanan

Pharmacoepidemiology · 2022

DOI: 10.3390/pharma1030010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacoepidemiology, 2022. Verfasst von Tianyu Sun und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island, Kingston, RI 02881, USA. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health (NIH).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Opioid use disorder (OUD) is a chronic disease requiring long-term treatment and is associated with opioid overdose and increased risk of mortality. However, existing randomized clinical trials focused on short-term treatment engagement and detoxification rather than overdose or mortality risk due to limited follow-up time and ethical considerations. We used a hypothetical trial framework to conduct a retrospective cohort study to assess the effectiveness of time-varying buprenorphine-naloxone on opioid overdose and death. We identified 58,835 insured adult patients with OUD diagnosis in the US, 2010–2017. We fit a marginal structural model using inverse probability weighting methods to account for measured baseline and time-varying confounders, as well as selection bias due to possibly differential loss-to-follow-up. We found that receipt of buprenorphine-naloxone was associated with reduced risk of opioid overdose (hazard ratio (HR) = 0.66, 95% confidence interval (CI): 0.49, 0.91), death (HR = 0.24, 95% CI: 0.08, 0.75), and overdose or death (HR = 0.58, 95% CI: 0.40, 0.84). The E-value for death was 7.8, which was larger than the upper 95% CI of the association between each measured baseline variable and all-cause death, which implies that the unmeasured confounding itself may not explain away the estimated effect of treatment on the endpoint of all-cause mortality.

Schlagwörter

Stichwörter der Autor:innen

administrative claimsbuprenorphine naloxonecausal inferencemarginal structural modelsopioid overdose

Autor:innen und Institutionen

  • Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island, Kingston, RI 02881, USA.
  • Department of Computer Science and Statistics, College of Art and Science, University of Rhode Island, Kingston, RI 02881, USA.
  • Department of Epidemiology, Brown University School of Public Health, Providence, RI 02903, USA.
  • The Warren Alpert Medical School of Brown University, Providence, RI 02903, USA.

ORCID-Profile: Tianyu Sun, Jeffrey Bratberg

Förderung

  • NIGMS NIH HHS
  • National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health (NIH)

Zitieren

APA

Sun, T., Katenka, N., Kogut, S., Bratberg, J., Rich, J., & Buchanan, A. (2022). Evaluation of the Effectiveness of Buprenorphine-Naloxone on Opioid Overdose and Death among Insured Patients with Opioid Use Disorder in the United States. Pharmacoepidemiology. https://doi.org/10.3390/pharma1030010

Vancouver

Sun T, Katenka N, Kogut S, Bratberg J, Rich J, Buchanan A. Evaluation of the Effectiveness of Buprenorphine-Naloxone on Opioid Overdose and Death among Insured Patients with Opioid Use Disorder in the United States. Pharmacoepidemiology. 2022. doi:10.3390/pharma1030010

BibTeX
@article{Sun2022,
  author = {Sun, Tianyu and Katenka, Natallia and Kogut, Stephen and Bratberg, Jeffrey and Rich, Josiah and Buchanan, Ashley},
  title = {Evaluation of the Effectiveness of Buprenorphine-Naloxone on Opioid Overdose and Death among Insured Patients with Opioid Use Disorder in the United States},
  journal = {Pharmacoepidemiology},
  year = {2022},
  doi = {10.3390/pharma1030010}
}
Kostenlos starten →